Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication
Use of an investigational product within 30 days or 5 half-lives, whichever is longer, preceding Study Day 0.
Treatment with any investigational drug within 30 days or 5 half-lives of the investigational drug, whichever is longer
Any investigational drug within 30 days or five half-lives (whichever is longer) preceding the first dose of SB-485232
Use of an investigational drug outside this study within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study medication.
Use of an investigational product (IP) within 30 days or 5 half-lives, whichever is longer, preceding Study Day 0.
Use of an investigational drug within 14 days or five half-lives (whichever is longer) preceding the first dose of study drug.
Use of an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study drug
Use of any investigational drug within 28 days or 5 half-lives, whichever is longer, preceding enrollment
Administration of any investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study treatment
Investigational drug; 30 days or five half-lives, whichever is longer, from last dose
Any investigational drug therapy less than 28 days or 3 half-lives (whichever is longer) prior to first dose of study treatment
Administration of an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study treatment
Administration of an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study treatment.
Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication
Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of investigational product (eltrombopag/placebo)
Treatment with an investigational drug within 30 days or 5 half lives, whichever is longer, preceding the first dose of study medication.
Administration of an investigational study treatment within 28 days or 5 half-lives, whichever is longer, preceding the first dose of study treatment(s) in this study
Use of any investigational drug within 28 days or 5 half-lives, whichever is longer, preceding enrollment; for the purposes of this study, bevacizumab will not be considered investigational therapy
Used an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study medication.
Used an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of protocol treatment;
Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication
Use of any investigational drug within 30 days or 5 half-lives, whichever is longer, preceding enrollment
